Antiphospholipid Syndrome Clinical Trial
Official title:
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
The purpose of this study is to determine whether a drug named Fluvastatin is beneficial and safe in reducing the risk of cardiovascular disease and blood clots in patients with antiphospholipid antibodies or Antiphospholipid Syndrome (APS).
The primary objective of the study is to determine the effects of fluvastatin on
pro-thrombotic and pro-inflammatory markers in aPL-positive lupus and non-lupus patients
(primary endpoint) and to determine the safety of fluvastatin in aPL-positive lupus and
non-lupus patients (secondary endpoint).
All eligible patients will sign an IRB-approved consent form during the screening visit and
give blood for baseline laboratory tests. Within a week of the screening visit, all patients
will be started on Fluvastatin 40 mg daily for three months. At three months patients will be
instructed to stop the study medication and they will be followed for another three months.
Thus, the total duration of the study is six months: first three months is interventional and
the last three months is observational.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
| Completed |
NCT00537290 -
A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome
|
Phase 2 | |
| Recruiting |
NCT00616317 -
Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
|
||
| Recruiting |
NCT00198068 -
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
|
||
| Completed |
NCT00180817 -
Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.
|
||
| Completed |
NCT03682419 -
Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
|
N/A | |
| Not yet recruiting |
NCT03303508 -
Measurement of Anti-dsDNA by Both CLIFT & ELISA
|
N/A | |
| Recruiting |
NCT04262492 -
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
|
||
| Withdrawn |
NCT00180778 -
Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05583305 -
Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome
|
||
| Recruiting |
NCT05644210 -
Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
|
||
| Recruiting |
NCT02303171 -
Use of Warfarin After the First Trimester in Pregnant Women With APS
|
Phase 4 | |
| Not yet recruiting |
NCT06420154 -
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
|
Early Phase 1 | |
| Recruiting |
NCT05859997 -
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
|
N/A | |
| Recruiting |
NCT06373003 -
Negative Antiphospholipid Syndrome: a Multicentric Study
|
||
| Recruiting |
NCT06373926 -
Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
|
N/A | |
| Recruiting |
NCT01818505 -
The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome
|
N/A | |
| Completed |
NCT00878137 -
Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin
|
N/A | |
| Completed |
NCT01104337 -
Drug Interaction Between Paracetamol and Warfarin
|
Phase 4 | |
| Completed |
NCT05313048 -
Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination
|